These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 17275980)

  • 61. Neurogenic detrusor overactivity treated with english botulinum toxin a: 8-year experience of one single centre.
    Del Popolo G; Filocamo MT; Li Marzi V; Macchiarella A; Cecconi F; Lombardi G; Nicita G
    Eur Urol; 2008 May; 53(5):1013-19. PubMed ID: 17950989
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Criteria and best clinical practice guidelines for first intradetrusor injection of botulinum toxin type A to treat neurogenic detrusor overactivity].
    Perrouin-Verbe B; Ruffion A; Gamé X; Denys P; Kerdraon J; Karsenty G; de Sèze M; Haab F; Saussine C; Soler JM; Amarenco G; Chartier-Kastler E
    Prog Urol; 2009 Jun; 19(6):372-82. PubMed ID: 19467455
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Botulinic toxin in patients with neurogenic dysfunction of the lower urinary tracts].
    Mazo EB; Krivoborodov GG; Shkol'nikov ME
    Urologiia; 2004; (4):44-8. PubMed ID: 15457954
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Using botulinum toxin for pelvic indications in women.
    Rao A; Abbott J
    Aust N Z J Obstet Gynaecol; 2009 Aug; 49(4):352-7. PubMed ID: 19694687
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The application of botulinum toxin in the prostate.
    Chuang YC; Chancellor MB
    J Urol; 2006 Dec; 176(6 Pt 1):2375-82. PubMed ID: 17085104
    [TBL] [Abstract][Full Text] [Related]  

  • 66. In vivo effects of botulinum toxin A on visceral sensory function in chronic spinal cord-injured rats.
    Khera M; Somogyi GT; Salas NA; Kiss S; Boone TB; Smith CP
    Urology; 2005 Jul; 66(1):208-12. PubMed ID: 15992889
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Botulinum toxin a era: little steps towards a better understanding.
    Del Popolo G
    Eur Urol; 2008 Jul; 54(1):25-7. PubMed ID: 18207634
    [No Abstract]   [Full Text] [Related]  

  • 68. Trigonal injection of botulinum toxin-A does not cause vesicoureteral reflux in neurogenic patients.
    Mascarenhas F; Cocuzza M; Gomes CM; Leão N
    Neurourol Urodyn; 2008; 27(4):311-4. PubMed ID: 17914742
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Botulinum toxin treatment of urethral and bladder dysfunction.
    Yokoyama T; Kumon H; Smith CP; Somogyi GT; Chancellor MB
    Acta Med Okayama; 2002 Dec; 56(6):271-7. PubMed ID: 12685855
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Re: Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity.
    Sahai A; Dowson C; Khan MS; Dasgupta P
    BJU Int; 2008 Feb; 101(4):515-6; author reply 516-7. PubMed ID: 18234066
    [No Abstract]   [Full Text] [Related]  

  • 71. Urodynamic assessment of poor responders after botulinum toxin-A treatment for overactive bladder.
    Sahai A; Khan MS; Le Gall N; Dasgupta P;
    Urology; 2008 Mar; 71(3):455-9. PubMed ID: 18342186
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Short-term efficacy of botulinum toxin a for refractory overactive bladder in the elderly population.
    White WM; Pickens RB; Doggweiler R; Klein FA
    J Urol; 2008 Dec; 180(6):2522-6. PubMed ID: 18930481
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Clinical Application of Botulinum Neurotoxin in Lower-Urinary-Tract Diseases and Dysfunctions: Where Are We Now and What More Can We Do?
    Kuo HC
    Toxins (Basel); 2022 Jul; 14(7):. PubMed ID: 35878235
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Suburothelial myofibroblasts in the human overactive bladder and the effect of botulinum neurotoxin type A treatment.
    Roosen A; Datta SN; Chowdhury RA; Patel PM; Kalsi V; Elneil S; Dasgupta P; Kessler TM; Khan S; Panicker J; Fry CH; Brandner S; Fowler CJ; Apostolidis A
    Eur Urol; 2009 Jun; 55(6):1440-8. PubMed ID: 19054608
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Prospective study of the clinical and urodynamic results of intradetrusor botulinum toxin injections for the treatment of neurogenic overactive bladder].
    Bentaleb Y; Castel-Lacanal E; Sallusto F; De Boissezon X; Malavaud B; Marque P; Rischmann P; Gamé X
    Prog Urol; 2008 Jul; 18(7):449-55. PubMed ID: 18602606
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Botulinum Toxin A for Bladder Pain Syndrome/Interstitial Cystitis.
    Chiu B; Tai HC; Chung SD; Birder LA
    Toxins (Basel); 2016 Jul; 8(7):. PubMed ID: 27376330
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Editorial comment on: Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections.
    Novara G
    Eur Urol; 2008 Mar; 53(3):618-9. PubMed ID: 17804151
    [No Abstract]   [Full Text] [Related]  

  • 78. Early effect on the overactive bladder symptoms following botulinum neurotoxin type A injections for detrusor overactivity.
    Kalsi V; Apostolidis A; Gonzales G; Elneil S; Dasgupta P; Fowler CJ
    Eur Urol; 2008 Jul; 54(1):181-7. PubMed ID: 18191323
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The use of botulinum toxin A injection for the management of external sphincter dyssynergia in neurologically normal children.
    Franco I; Landau-Dyer L; Isom-Batz G; Collett T; Reda EF
    J Urol; 2007 Oct; 178(4 Pt 2):1775-9; discussion 1779-80. PubMed ID: 17707430
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Health economics and intradetrusor injections of botulinum for the treatment of detrusor overactivity.
    Sangster P; Kalsi V
    BJU Int; 2008 Jul; 102 Suppl 1():17-9. PubMed ID: 18665974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.